patient subgroup...
Age < 65y (younger) Age > 65y Age > 75y (older) Asian type cell type, non squamous cell cell type, squamous cell ECOG 0 ECOG 1 Gender, female Gender, male metastasis (bone) metastasis (brain) NO metastasis (brain) YES metastasis (liver ) PD-L1 < 1% PD-L1 > 1% PDL1 (TC0 and IC0 : <1% of TC and IC) PDL1 (TC1/2 or IC1/2 : ≥1% of TC or IC and <50% of TC and <10% of IC) PDL1 (TC1/2/3 or IC1/2/3 : ≥1% of TC or IC) PDL1 (TC3 or IC3 : ≥50% of TC or ≥10% of IC ) smoker (current or former) smoker (never) stage III (locally advanced) stage IV (metastatic)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
mNSCLC - L1 - all population, immune chekpoint inhibitors versus placebo plus SoC, meta-analysis of study results
Outcome
Relative effect 95%CI
LoD
Trt. better when
I2
k (RCT/OBS)
Bayesian probability
Overall ROB
Publication bias
Degree of certainty
Endpoint importance
Published MA
efficacy endpoints 00 deaths (OS) 0.61 [0.40, 0.93]< 1 0% 1 study (1/-) 99.0 % NA not evaluable crucial - progression or deaths (PFS) 0.48 [0.36, 0.64]< 1 0% 1 study (1/-) 100.0 % NA not evaluable important - objective responses (ORR) 2.54 [1.63, 3.97]> 1 0% 1 study (1/-) 100.0 % NA not evaluable non important - safety endpoints 00 AE (any grade) 1.02 [0.03, 30.46]< 1 0% 1 study (1/-) 49.7 % NA not evaluable non important - AE (grade 3-4) 1.13 [0.74, 1.73]< 1 0% 1 study (1/-) 29.1 % NA not evaluable non important - AE leading to death (grade 5) 0.31 [0.11, 0.90]< 1 0% 1 study (1/-) 98.4 % NA not evaluable non important - AE leading to treatment discontinuation (any grade) 0.70 [0.31, 1.55]< 1 0% 1 study (1/-) 81.1 % NA not evaluable non important - AE leading to treatment discontinuation (grade 3-4) 0.64 [0.26, 1.56]< 1 0% 1 study (1/-) 83.6 % NA not evaluable non important - TRAE (grade 3-4) endpoints 00 Diarrhoea TRAE (grade 3-4) 0.49 [0.01, 24.91]< 1 0% 1 study (1/-) 63.6 % NA not evaluable non important - Hyperthyroidism TRAE (grade 3-4) 0.49 [0.01, 24.91]< 1 0% 1 study (1/-) 63.6 % NA not evaluable non important - Hypothyroidism TRAE (grade 3-4) 0.49 [0.01, 24.91]< 1 0% 1 study (1/-) 63.6 % NA not evaluable non important - Increase AST TRAE (grade 3-4) 0.49 [0.01, 24.91]< 1 0% 1 study (1/-) 63.6 % NA not evaluable non important - Increased ALT TRAE (grade 3-4) 0.49 [0.01, 24.91]< 1 0% 1 study (1/-) 63.6 % NA not evaluable non important - Pneumonitis TRAE (grade 3-4) 0.98 [0.09, 10.96]< 1 0% 1 study (1/-) 50.5 % NA not evaluable non important - Pruritus TRAE (grade 3-4) 0.49 [0.01, 24.91]< 1 0% 1 study (1/-) 63.6 % NA not evaluable non important - Rash TRAE (grade 3-4) 0.16 [0.02, 1.56]< 1 0% 1 study (1/-) 94.1 % NA not evaluable non important - AE (grade 3-4) endpoints 00
LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias;
suggested: nominally statistically significant but without a strict control of overall risk of type 1 error;
inconclusive: not nominally statistically significant;
safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies;
published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE.
Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.